Videos Library
What do we call KOLs if we can’t call them “KOLs”?
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Overview
- The term “KOL”: Too toxic for everyday use, or still the best tool for the job?
- Results from a survey of pharma and KOLs on the use of terminology alternatives.
- Should pharma work towards using one universal replacement for the term “KOL”?
- How does this change the way we engage with KOLs and stakeholders in medical affairs?
- And what exactly do KOLs think of all this?
Speaker
Sanjay Singhvi
Director
System Analytic, UK
Subscribe or unlock this video to download the presentation slides. If you already have an account, please log in.
REMINDER
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of Evidence Life Science.
Sponsor
